Here are the 10-K annual reports from Omeros Corporation (OMER) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow OMER and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMER filings page.
Omeros Corporation reports its annual results and outlines a major strategic shift toward complement-mediated diseases, oncology, and infectious disease therapies. Its lead product, YARTEMLEA (narsoplimab-wuug), became the first FDA‑approved treatment for TA‑TMA on December 23, 2025, with U.S. sales starting in January 2026.
Omeros also completed an Asset Purchase and License Agreement with Novo Nordisk, granting global rights to MASP‑3 antibody zaltenibart for an upfront $240.0 million, up to $1.8 billion in potential milestones, plus tiered royalties. The company maintains a diversified pipeline, including MASP‑2 programs OMS1029 and additional indications for narsoplimab, PDE7 program OMS527 for addiction and movement disorders, the OncotoX‑AML oncology candidate approaching IND‑enabling completion, and the T‑CAT infectious disease platform targeting multidrug‑resistant organisms.